lncRNA linc-UBC1 在恶性肿瘤发生发展中的作用研究进展

来源期刊：广州医药 | 323-329 发布时间：2025-03-20 收稿时间：2025/4/9 16:00:50 阅读量：124

作者：: 娄焕英,

范晓宇,

季莹莹,

王凤,

李毅,

冯强,

关键词：: 长链非编码RNA linc-UBC1 恶性肿瘤调控机制; long non-coding RNA linc-UBC1 malignant tumor mechanisms of regulation

DOI：: 10. 20223 / j. cnki. 1000-8535. 2025. 03. 005

收稿时间：: 2024-04-17
修订日期：
接收日期：
引用总数：: 0

长链非编码RNA（lncRNA）是一类长度大于200个核苷酸转录本，通过调控DNA、RNA及蛋白质的表达和功能，参与肿瘤发生、发展并发挥重要作用的RNA，近年来lncRNA成为恶性肿瘤早期诊断和预后标志物研究新的关注方向。Linc-UBC1作为一种新发现的lncRNA，在多种恶性肿瘤如肺癌、胃癌、结直肠癌、宫颈癌、卵巢癌、食管鳞癌等中异常高表达，可通过作为竞争性RNA（ceRNA）、参与信号通路等促进肿瘤细胞的增殖、迁移、侵袭、细胞周期进展、细胞凋亡和上皮间充质转化（EMT）等过程；高表达的linc-UBC1能够增加恶性肿瘤的耐药性，其表达水平与肿瘤分期、淋巴结转移和原发肿瘤远处转移呈正相关；linc-UBC1有望成为许多恶性肿瘤的新型的生物标志物、预后预测因子和治疗靶点，但其具体的调控机制仍处于研究的早期阶段，有待进一步深入研究。文章就目前linc-UBC1在恶性肿瘤发生和发展中的作用研究进展进行综述。

长链非编码RNA（long non-coding RNA，lncRNA）是由200多个核苷酸组成，不编码蛋白质，约76%的人类基因组被转录生成lncRNA^［1］。它们位于细胞核和细胞质中，人类恶性肿瘤的发生和发展与其调控失常密切相关^［2］。LncRNA在正常组织及肿瘤组织中的表达存在显著的不同，lncRNA既可以与DNA发生相互作用调控基因转录，也可以与RNA或者蛋白质相互作用后转录调控蛋白活性，影响细胞的增殖、凋亡和侵袭等^［3］。近年来lncRNA成为恶性肿瘤早期诊断和预后标志物新的研究方向^［4］，lncRNA可以作为多种恶性肿瘤的潜在诊断或预后标志物^［5］。其中linc-UBC1作为lncRNA中的一种，在多种恶性肿瘤中发挥着重要作用。

1 linc-UBC1 概述

Linc-UBC1又被称长链非编码RNA 膀胱癌相关转录本1（lncRNA BLACAT1），只有1个外显子，位于人类染色体1q32.1上，大小为2 616 kb。它可以直接与多种蛋白相互作用或充当相应微RNA（microRNA，miRNA）的“海绵”来调控ATG7、EZH2等下游靶基因，从而影响恶性肿瘤的发生和发展，其中包括直接调节肿瘤相关蛋白的表达水平，以及通过整合特定的miRNAs（如miR-144和miR-361）进行复杂的调控网络构建。这些miRNAs在细胞内发挥着关键的调节作用，能够影响肿瘤细胞的增殖、凋亡、侵袭及转移等关键过程，从而直接或间接地诱发或促进恶性肿瘤的形成。Linc-UBC1首先在膀胱癌（bladder carcinoma，BC）中被发现高表达，继而在多种人类恶性肿瘤中被发现异常表达^［6］，作为一种致癌因子参与细胞增殖、迁移、侵袭、细胞周期进展、细胞凋亡和EMT等过程。此外，linc-UBC1与肿瘤临床分期、肿瘤大小、淋巴结转移和远处转移呈正相关^［7］，过表达导致总生存期和无进展生存期较短。因此，linc-UBC1在多种恶性肿瘤中高表达可能是导致预后不良的原因^［8］。

对于早期的恶性肿瘤患者，目前有多种治疗方法，如肿瘤根治性切除术、放射治疗和化学治疗、射频消融等^［9］，然而，对于晚期的患者，可以使用的治疗方法非常有限，因而寻找早期诊断的生物标志物和治疗的靶点，在临床上具有重要意义^［10］。随着全基因组测序技术的普及，基因组学和生物信息学分析的整合，为恶性肿瘤的早期筛查提供了可能。尽管如此，在特定恶性肿瘤类型中发现的生物标记物在其他恶性肿瘤中可能并不具有一致的功能。因此，需要寻找一种广泛早期诊断、预测肿瘤转移和预后的生物标志物应用于临床诊断^［11］。linc-UBC1有望成为多种恶性肿瘤的新型的生物标志物、治疗靶点和预后预测因子。

2 linc-UBC1 在人类恶性肿瘤中的异常表达

2.1 肺癌

肺癌是指原发于气管、支气管和肺的恶性肿瘤，其发病率和死亡率正在迅速上升。肺癌可分为小细胞肺癌和非小细胞肺癌，后者又分为肺腺癌、鳞状细胞癌和大细胞癌^［12］。为了提高肺癌的早期诊断率，近年来出现了计算机断层扫描、支气管镜检查和痰细胞学分析^［13］。对于肺癌的个性化治疗，手术切除联合铂类化疗和免疫治疗已被证明是有效的^［14］。然而，早期诊断和治疗的进展仍远不能令人满意，需要寻找更可靠的生物标志物和治疗靶点。研究显示，linc-UBC1在NSCLC中发挥着重要作用^［15］。在前人的研究中，linc-UBC1在肺癌组织中的表达与相邻正常组织中相比明显上调，提示linc-UBC1可能在肺癌中起致癌基因作用^［16］。Linc-UBC1高表达的患者总生存期和无进展生存期较低表达的患者短。体外研究表明，linc-UBC1的下调抑制了细胞的增殖、迁移和侵袭。当linc-UBC1沉默时，上皮-间充质转化也受到抑制，经过介导Wnt/β-catenin信号通路，E-cadherin表达增加，波形蛋白表达减少。LincUBC1在顺铂（DDP）耐药NSCLC细胞中上调，并通过miR-17/ATG7信号通路促进NSCLC细胞的自噬和化疗耐药^［17］。因此，linc-UBC1可能作为NSCLC潜在的生物标志物和新的治疗靶点。

2.2 胃癌

胃癌是最常见的消化道恶性肿瘤，预后较差^［18］。由于缺乏可靠的筛查方法，胃癌患者在初诊时往往处于晚期，因此更易发生转移^［19-20］。为了能早期诊断，应该寻找新的GC的生物标志物。Wang等^［21］采用实时荧光定量逆转录聚合酶链反应（RT-qPCR）R检测胃癌组织中linc-UBC1 miR-149-5p和KIF2A的表达。他们应用MTT法、创面愈合法和Transwell法检测体外培育的胃癌细胞的增殖、迁移和侵袭能力，构建裸鼠异种移植瘤模型，验证linc-UBC1基因敲除对胃癌的抑制作用，然后采用双萤光素酶报告基因法检测lincUBC1、miR-149-5p和KIF2A之间的相互作用，Western blot检测KIF2A蛋白表达。结果显示，胃癌中miR-149-5p表达下调，linc-UBC1、KIF2A表达上调，敲减linc-UBC1可在体外抑制胃癌细胞的增殖、迁徙和侵袭，在体内可抑制恶性肿瘤的发展。此外，linc-UBC1作为miR-149-5p的分子海绵上调KIF2A的表达，linc-UBC1通过调控miR-149-5p/KIF2A轴，加速了胃癌细胞的增殖、迁移和侵袭。因此，linc-UBC1通过调控miR-149-5p/KIF2A轴促进胃癌的发生，linc-UBC1/miR-149-5p/KIF2A级联可能是新的治疗靶点。linc-UBC1可能是一种新的胃癌早期诊断、预后生物标志物和潜在的治疗靶点^［22］。

2.3 结直肠癌

结直肠癌是世界范围内多见的恶性肿瘤^［23］，是全球癌症相关死亡的最常见原因。尽管近年来对结直肠癌发病分子机制的认识有了进步，并且实施了更有效的药物治疗，但患者的总体生存率仍然令人不满意。高死亡率主要是由于大约一半患者出现肿瘤转移和癌细胞耐药群体。LncRNA已成为结直肠癌诊断和预后以及预测药物治疗反应的非侵入性恶性肿瘤生物标志物的新来源^［24］。Su等^［25］通过研究发现，linc-UBC1的表达升高是结直肠癌的一个独立的不利预后指标，并揭示了敲低linc-UBC1表达可抑制肿瘤增殖，体内外研究结果均是如此。他们采用RT-qPCR检测结直肠癌组织和细胞中lncRNA linc-UBC1、miR-519d-3p和cAMP响应元件结合蛋白1（cAMP-responsive element binding protein 1，CREB1）的表达水平；采用MTT、流式细胞术和transwell法检测其生物性能效应，采用奥沙利铂（oxaliplatin，OXA）给药进行药敏试验，通过starBase在线软件预测miR-519d-3p与linc-UBC1或CREB1的潜在结合位点，用双萤光素酶报告基因分析法证明，用蛋白免疫印迹法检测结直肠癌细胞中相关蛋白的表达。结果表明，linc-UBC1在结直肠癌组织和细胞中表达上调，并与TNM分期、远处转移及总生存率相关，linc-UBC1的敲低抑制了结直肠癌细胞的增殖、迁移和侵袭，促进了细胞凋亡，并使OXA耐药细胞再次致敏，miR-519d-3p是linc-UBC1的靶点，miR-519d-3p的缺失逆转了linc-UBC1缺失对结直肠癌细胞的积极作用，此外，数据显示，miR-519d-3p直接靶向CREB1和linc-UBC1海绵化miR-519d-3p调控CREB1的表达。Linc-UBC1通过miR-519d-3p/CREB1轴介导结直肠癌的发生、发展和OXA耐药的发生。因此，linc-UBC1可作为结直肠癌的新的生物标志物和治疗靶点。

2.4 宫颈癌

宫颈癌是最常见的妇科恶性肿瘤，严重威胁女性的生命健康。据估计，全球每年有超过50万例患者被诊断宫颈癌和超过30万例相关死亡，宫颈癌是仅次于乳腺癌的第二大女性恶性肿瘤类型，发展中国家宫颈癌的发病率和死亡率分别为83%和87%^［26］。尽管针对HPV的疫苗降低了感染的发生率，并且早期诊断的治疗效果有所提高，但由于宫颈癌患者的耐药、转移和侵袭的发展导致治疗失败，预后仍然令人沮丧^［27］。为了进一步提高早期诊断和总体生存率，需要寻找新的生物标志物和治疗靶点^［28］。一些lncRNA已被确定为导致癌基因失调和宫颈癌进展的原因，Cheng 等^［29］研究发现，与相邻的癌旁组织比较，宫颈癌患者的linc-UBC1在癌组织中表达上调。宫颈癌组织中，linc-UBC1高表达的患者总生存期以及无进展生存期更短。Linc-UBC1表达与多种肿瘤miRNA如miR-424和miR-143的表达呈负相关，linc-UBC1过表达导致miR-424和miR-143下调，如果miR-424和miR-143上调，则抑制宫颈癌细胞的迁移和侵袭，而linc-UBC1过表达促进CC细胞的迁移和侵袭。此外，过表达miR-424和miR-143可减弱linc-UBC1过表达的影响，因此过表达linc-UBC1可能通过下调miR-424和miR-143促进宫颈癌的进展。Western blot实验显示，在ME180和C33A细胞中，敲低linc-UBC1后，细胞周期B1、细胞分裂周期25C、N-cadherin蛋白水平降低，而E-cadherin蛋白水平升高^［30］。这些发现能够预见linc-UBC1在宫颈癌中的致癌潜力，有助于研究人员了解lncRNA作为生物标志物的作用机制，以及人工智能在克服化疗耐药和放疗耐药方面的临床靶向研究进展，从而改善宫颈癌的治疗。

2.5 卵巢癌

卵巢癌是女性生殖系统中最常见的三大恶性肿瘤之一，由于5年生存率低，其发病率虽低于宫颈癌和子宫内膜癌，死亡率却高居女性生殖系统恶性肿瘤之首，严重威胁着女性的生命健康。卵巢恶性肿瘤生长部位隐匿，且容易转移，早期恶性肿瘤无明显症状，缺乏特异性的早期诊断的生物标志物，因此当明确诊断为卵巢癌时，约70%的患者已经处于晚期。因此，寻找卵巢癌早期诊断生物标志物和治疗靶点尤为重要。研究发现，与癌旁组织相比，卵巢癌组织中linc-UBC1的表达会明显上调^［31］。卵巢癌患者TNM期别越晚，linc-UBC1水平表达水平越高；小于5 cm的卵巢癌组织中linc-UBC1表达水平低于≥5 cm的卵巢癌组织。淋巴结转移的卵巢癌患者体内linc-UBC1的表达显著升高，同样远处转移卵巢癌患者亦是如此。因此证明linc-UBC1在卵巢癌组织和细胞中明显上调，而且诱导卵巢癌的增殖和转移。在体外，linc-UBC1敲低可抑制卵巢癌细胞的增殖、迁移和侵袭。Yang等^［32］也报道了linc-UBC1沉默可诱导细胞周期阻滞于G0/G1期，而linc-UBC1对细胞凋亡和自噬的影响尚不清楚。进一步的研究发现，linc-UBC1通过调节miR-519d-3p/核糖体蛋白S15A轴激活Wnt/β-catenin信号通路^［33］。这将表明linc-UBC1有望成为卵巢癌的新型肿瘤标志物和治疗靶点。然而，由于卵巢癌的发病机制比较复杂，多种基因调控机制参与其中，详细的作用机制有待进一步探索，但随着相关研究的深入，探究linc-UBC1的作用机制可对其他因子的探索提供一定的依据，也可能成为卵巢癌靶向药的一个方向。

2.6 食管鳞癌

食管癌是一种常见的上消化道恶性肿瘤，发病率高，目前被列为全球第八大癌症，总体5年生存率约为20%，其中鳞癌在高发区占80%以上^［34］。食管癌的主要治疗方法包括手术治疗、放射治疗、化学治疗和综合治疗等，对于晚期患者仍效果不佳。因为其发病机制尚不明确，需要早期诊断标志物及治疗靶点的发现。研究发现，linc-UBC1在食管鳞癌（esophageal squamous cell carcinoma，ESCC）中也有一定作用和机制^［35］。在ESCC组织中，linc-UBC1的表达水平明显升高，这通过RT-qPCR检测得到验证。linc-UBC1的高表达与ESCC的临床特征如TNM分期（肿瘤-淋巴结-转移）和淋巴结转移等密切相关，这表明linc-UBC1可能参与了ESCC的进展和转移过程。采用Kaplan-Meier法分析显示，linc-UBC1高表达的ESCC患者的总生存期显著短于低表达患者。这一发现提示linc-UBC1可能是影响ESCC预后的重要因素。通过伤口愈合实验和细胞侵袭实验发现，linc-UBC1的下调显著抑制了ESCC细胞的迁移和侵袭能力。这表明linc-UBC1在促进ESCC细胞恶性行为方面发挥了重要作用。采用免疫印迹法和萤光素酶法进一步探讨了linc-UBC1在ESCC中的作用机制。研究发现linc-UBC1可能通过调控某些关键蛋白（如EZH2和E-cadherin）的表达来影响ESCC细胞的迁移和侵袭能力。具体而言，linc-UBC1可能通过上调EZH2和下调E-cadherin来促进ESCC细胞的恶性转化和转移。因此，linc-UBC1可能是一种新的致癌基因，为ESCC的早期诊断和治疗提供了可能的新靶点。

3 lncRNA linc-UBC1 在人类恶性肿瘤中的生物学机制

3.1 与miRNA的相互作用

越来越多的证据表明，lncRNA通过竞争性结合共享miRNA作为内源性竞争性RNA（competing endogenous RNA，ceRNA），从而影响其同源基因和非相关基因，在各种人类恶性肿瘤的发生、发展中发挥了突出的作用^［36］。因此，有报道称miR-142-5p^［37］、miR-144、miR-485-5p^［38］、miR-424和miR-143参与了linc-UBC1的致癌活性，但其下游靶点及其与信号通路或生物分子的相互作用仍需进一步研究。此外，linc-UBC1通过miR-605-3p/VAS、miR-503/Bcl-2、miR-150-5p/CCR2、miR-17/ATG7、miR-361/ABCB1和miR-519d-3p/RPS15A轴发挥其致癌作用，可作为临床干预的潜在靶点。

3.2 参与信号通路

已经认识到Wnt/β-catenin信号和STAT3信号通常在多种人类恶性肿瘤中被激活，促进其恶性表型的出现^［39-40］，这也在linc-UBC1的功能表达过程中被观察到。在Wnt/β-catenin信号传导过程中，作为关键调控蛋白之一的β-catenin可被lincUBC1从mRNA和蛋白水平上抑制。进一步分析表明，linc-UBC1主要影响β-catenin的细胞核表达，而不影响细胞质表达，此外，c-myc和cyclin D1与β-catenin在linc-UBC1活性上是平行的。Wang等^［41］也报道，Wnt/β-catenin信号传导的主要靶基因MMP-7因linc-UBC1过表达而升高，从而促进细胞迁移和侵袭。而在STAT3信号传导中，linc-UBC1主要通过STAT3 Tyr705位点的磷酸化发挥致癌活性。

3.3 其他生物蛋白质和分子

Linc-UBC1在细胞核中富集，在细胞核中的表达明显高于细胞质，这表明linc-UBC1可能在转录水平上具有主要的调节功能^［42］。近年来，在linc-UBC1的活性中也发现了其他生物蛋白或分子。PSEN1是一种与放射治疗敏感性相关的蛋白，可介导linc-UBC1的致癌活性^［43］。Su等^［25］的研究揭示了linc-UBC1在肿瘤表观遗传学调控中的新角色。它通过与EZH2或HDAC1的直接结合，调节PRC2的募集和肿瘤抑制基因启动子区的组蛋白甲基化水平，从而影响肿瘤抑制基因的表达。这一发现为深入理解肿瘤发生发展的表观遗传学机制提供了新的视角，并可能为肿瘤的治疗提供新的靶点。

综上所述，人类恶性肿瘤侵袭转移频繁，治疗难度大^［44-45］，研究有效的治疗靶点迫在眉睫。LncRNA在转录和翻译水平调控基因表达方面具有多种作用，已有报道称其参与肿瘤发生和肿瘤转移^［46］。此外，lncRNA还能调节癌细胞对化学治疗和放射治疗的敏感性^［47-49］。LncRNA linc-UBC1作为一颗冉冉升起的新星，逐渐展现出临床应用的潜力。在多种恶性肿瘤中，linc-UBC1的作用已经在以前的研究中被描述过，然而，具体的作用机制仍处于研究的早期阶段，有待进一步深入研究。首先，目前还不清楚在恶性肿瘤中参与linc-UBC1异常表达的调控因子，因此进一步的研究应该集中于linc-UBC1异常表达的上游机制，这可能为恶性肿瘤治疗开辟新的途径。其次，虽然有明确证据表明linc-UBC1在肿瘤发生、发展中发挥直接作用，但linc-UBC1在大多数恶性肿瘤中发挥作用的机制，特别是linc-UBC1介导的RBP调控的分子机制，仍需要高质量的研究来阐明。再次，仍需要更全面、更大规模、高质量的多中心研究来进一步证实其在各种恶性肿瘤中的预测价值。因此，总结linc-UBC1的功能作用可能为癌症治疗提供新的生物标志物和治疗方法，只有解决了上述这些问题，linc-UBC1才能更早地应用于临床。

1、BRIDGES%E2%80%83M%E2%80%83C%EF%BC%8CDAULAGALA%E2%80%83A%E2%80%83C%EF%BC%8CKOURTIDIS%E2%80%83A%EF%BC%8E%0ALNCcation%EF%BC%9AlncRNA%E2%80%83localization%E2%80%83and%E2%80%83function%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AJ%E2%80%83Cell%E2%80%83Biol%EF%BC%8C2021%EF%BC%8C220%EF%BC%882%EF%BC%89%EF%BC%9Ae202009045%EF%BC%8E

2、ZHANG%E2%80%83X%EF%BC%8CXIE%E2%80%83H%EF%BC%8CLUO%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83%20systematic%E2%80%83%0Areview%E2%80%83and%E2%80%83meta-analysis%E2%80%83of%E2%80%83long%E2%80%83noncoding%E2%80%83RNA%E2%80%83linc%02UBC1%E2%80%83expression%E2%80%83and%E2%80%83prognosis%E2%80%83and%E2%80%83clinicopathological%E2%80%83%0Aphenotypes%E2%80%83in%E2%80%83human%E2%80%83cancers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EArtif%E2%80%83%20Cells%E2%80%83%0ANanomed%E2%80%83Biotechnol%EF%BC%8C2020%EF%BC%8C48%EF%BC%881%EF%BC%89%EF%BC%9A875-884%EF%BC%8E

3、赵二勇，陈悦霖，易莉莎，等．LINC02038与子宫内膜癌发生、发展的关联性分析［J］．广州医药，2024，55（1）：18-24．

4、CHEN%E2%80%83X%EF%BC%8CDAI%E2%80%83M%EF%BC%8CZHU%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EEvaluation%E2%80%83on%E2%80%83the%E2%80%83%0Adiagnostic%E2%80%83and%E2%80%83%20prognostic%E2%80%83values%E2%80%83of%E2%80%83long%E2%80%83%20non-coding%E2%80%83%0ARNA%E2%80%83BLACAT1%E2%80%83in%E2%80%83common%E2%80%83types%E2%80%83of%E2%80%83human%E2%80%83cancer%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Cancer%EF%BC%8C2017%EF%BC%8C16%EF%BC%881%EF%BC%89%EF%BC%9A160%EF%BC%8E

5、XU%E2%80%83R%EF%BC%8CCAO%E2%80%83X%E2%80%83R%EF%BC%8CZHANG%E2%80%83B%E2%80%83Q%EF%BC%8Cet%E2%80%83al%EF%BC%8EBLACAT1%E2%80%83%0Ais%E2%80%83negatively%E2%80%83associated%E2%80%83with%E2%80%83prognosis%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83%0ANSCLC%E2%80%83and%E2%80%83inhibits%E2%80%83cell%E2%80%83progression%EF%BC%8Cmetastasis%E2%80%83and%E2%80%83%0Aepithelial-mesenchymal%E2%80%83transition%E2%80%83through%E2%80%83down%02regulating%E2%80%83Wnt%2F%CE%B2-catenin%E2%80%83signaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AEur%E2%80%83Rev%E2%80%83Med%E2%80%83Pharmacol%E2%80%83Sci%EF%BC%8C2019%EF%BC%8C23%EF%BC%8814%EF%BC%89%EF%BC%9A%0A6217-6225%EF%BC%8E

6、YAN%E2%80%83X%EF%BC%8CZHANG%E2%80%83N%EF%BC%8CWANG%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83prognostic%E2%80%83%0Asignificance%E2%80%83of%E2%80%83LncRNA%E2%80%83BLACAT1%E2%80%83overexpression%E2%80%83in%E2%80%83%0Avarious%E2%80%83tumors%EF%BC%9Aa%E2%80%83meta-analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83Genet%EF%BC%8C%0A2024%EF%BC%8815%EF%BC%89%EF%BC%9A1362420%EF%BC%8E

7、HAN%E2%80%83W%EF%BC%8CYU%E2%80%83F%EF%BC%8CGUAN%E2%80%83W%EF%BC%8EOncogenic%E2%80%83%20roles%E2%80%83%20of%E2%80%83%0AlncRNA%E2%80%83%20BLACAT1%E2%80%83%20and%E2%80%83its%E2%80%83%20related%E2%80%83%20mechanisms%E2%80%83in%E2%80%83%0Ahuman%E2%80%83cancers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Pharmacother%EF%BC%8C2020%0A%EF%BC%88130%EF%BC%89%EF%BC%9A110632%EF%BC%8E

8、WU%E2%80%83T%EF%BC%8CWANG%E2%80%83Q%EF%BC%8CDING%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EPrognostic%E2%80%83and%E2%80%83%0Aclinicopathological%E2%80%83%20significance%E2%80%83%20of%E2%80%83long%E2%80%83%20non-coding%E2%80%83%0ARNA%E2%80%83BLACAT1%E2%80%83in%E2%80%83cancer%EF%BC%9AAn%E2%80%83updated%E2%80%83meta-analysis%E2%80%83%0Aand%E2%80%83TCGA%E2%80%83data%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Lab%EF%BC%8C2020%EF%BC%8C66%0A%EF%BC%8811%EF%BC%89%EF%BC%8E

9、EL%E2%80%83SHARKAWI%E2%80%83F%E2%80%83Z%EF%BC%8CEL%E2%80%83SABAH%E2%80%83M%EF%BC%8CATYA%E2%80%83H%E2%80%83B%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EUrinary%E2%80%83BLACAT1%E2%80%83as%E2%80%83a%E2%80%83non-invasive%E2%80%83biomarker%20for%E2%80%83bladder%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Biol%E2%80%83Rep%EF%BC%8C2023%EF%BC%8C50%0A%EF%BC%885%EF%BC%89%EF%BC%9A4339-4345%EF%BC%8E

10、SUN%E2%80%83J%EF%BC%8CJIA%E2%80%83J%EF%BC%8CYUAN%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83BLACAT1%E2%80%83%0Aaccelerates%E2%80%83non-small%E2%80%83cell%E2%80%83lung%E2%80%83cancer%E2%80%83through%E2%80%83up%02regulating%E2%80%83the%E2%80%83activation%E2%80%83of%E2%80%83sonic%E2%80%83hedgehog%E2%80%83pathway%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83Oncol%EF%BC%8C2021%EF%BC%8811%EF%BC%89%EF%BC%9A625253%EF%BC%8E

11、HERMAN%E2%80%83A%E2%80%83B%EF%BC%8CTSITSIPATIS%E2%80%83D%EF%BC%8CGOROSPE%E2%80%83M%EF%BC%8E%0AIntegrated%E2%80%83%20lncRNA%E2%80%83%20function%E2%80%83%20upon%E2%80%83%20genomic%E2%80%83%20and%E2%80%83%0Aepigenomic%E2%80%83regulation%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83Mol%E2%80%83Cell%EF%BC%8C2022%EF%BC%8C82%0A%EF%BC%8812%EF%BC%89%EF%BC%9A2252-2266%EF%BC%8E

12、WANG%E2%80%83L%EF%BC%8CMA%E2%80%83Q%EF%BC%8CYAO%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8ECurrent%E2%80%83%20status%E2%80%83%0Aand%E2%80%83development%E2%80%83of%E2%80%83anti-PD-1%2FPD-L1%E2%80%83immunotherapy%E2%80%83%0Afor%E2%80%83lung%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83Immunopharmacol%EF%BC%8C2020%0A%EF%BC%8879%EF%BC%89%EF%BC%9A106088%EF%BC%8E

13、YOUSEFI%E2%80%83M%EF%BC%8CGHAFFARI%E2%80%83P%EF%BC%8CNOSRATI%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrognostic%E2%80%83and%E2%80%83therapeutic%E2%80%83significance%E2%80%83of%E2%80%83circulating%E2%80%83%0Atumor%E2%80%83cells%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83lung%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83Cell%E2%80%83%0AOncol%EF%BC%88Dordr%EF%BC%89%EF%BC%8C2020%EF%BC%8C43%EF%BC%881%EF%BC%89%EF%BC%9A31-49%EF%BC%8E

14、BODOR%E2%80%83JN%EF%BC%8CBOUMBER%E2%80%83Y%EF%BC%8CBORGHAEI%E2%80%83H%EF%BC%8E%0ABiomarkers%E2%80%83for%E2%80%83immune%E2%80%83checkpoint%E2%80%83inhibition%E2%80%83in%E2%80%83non%02small%E2%80%83cell%E2%80%83lung%E2%80%83cancer%EF%BC%88NSCLC%EF%BC%89%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83Cancer%EF%BC%8C%0A2020%EF%BC%8C126%EF%BC%882%EF%BC%89%EF%BC%9A260-270%EF%BC%8E

15、YE%E2%80%83J%E2%80%83R%EF%BC%8CLIU%E2%80%83L%EF%BC%8CZHENG%E2%80%83F%EF%BC%8ELong%E2%80%83%20noncoding%E2%80%83RNA%E2%80%83%0Abladder%E2%80%83cancer%E2%80%83associated%E2%80%83transcript%E2%80%83%201%E2%80%83%20promotes%E2%80%83the%E2%80%83%0Aproliferation%EF%BC%8Cmigration%EF%BC%8Cand%E2%80%83invasion%E2%80%83of%E2%80%83nonsmall%E2%80%83cell%E2%80%83%0Alung%E2%80%83cancer%E2%80%83through%E2%80%83sponging%E2%80%83miR-144%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDNA%E2%80%83%0ACell%E2%80%83Biol%EF%BC%8C2017%EF%BC%8C36%EF%BC%8810%EF%BC%89%EF%BC%9A845-852%EF%BC%8E

16、SHU%E2%80%83D%EF%BC%8CXU%E2%80%83Y%EF%BC%8CCHEN%E2%80%83W%EF%BC%8EKnockdown%E2%80%83of%E2%80%83lncRNA%E2%80%83%0ABLACAT1%E2%80%83reverses%E2%80%83the%E2%80%83resistance%E2%80%83of%E2%80%83afatinib%E2%80%83to%E2%80%83non%02small%E2%80%83cell%E2%80%83lung%E2%80%83cancer%E2%80%83via%E2%80%83modulating%E2%80%83STAT3%E2%80%83signalling%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Drug%E2%80%83Target%EF%BC%8C2020%EF%BC%8C28%EF%BC%883%EF%BC%89%EF%BC%9A300-306%EF%BC%8E

17、%E2%80%83%20HUANG%E2%80%83F%E2%80%83X%EF%BC%8CCHEN%E2%80%83H%E2%80%83J%EF%BC%8CZHENG%E2%80%83F%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ALncRNA%E2%80%83BLACAT1%E2%80%83is%E2%80%83involved%E2%80%83in%E2%80%83%20chemoresistance%E2%80%83%0Aof%E2%80%83%20non-small%E2%80%83%20cell%E2%80%83lung%E2%80%83%20cancer%E2%80%83%20cells%E2%80%83%20by%E2%80%83%20regulating%E2%80%83%0Aautophagy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Oncol%EF%BC%8C2019%EF%BC%8C54%EF%BC%881%EF%BC%89%EF%BC%9A%0A339-347%EF%BC%8E

18、KIM%E2%80%83S%E2%80%83T%EF%BC%8CCRISTESCU%E2%80%83R%EF%BC%8CBASS%E2%80%83A%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AComprehensive%E2%80%83molecular%E2%80%83characterization%E2%80%83of%E2%80%83clinical%E2%80%83%0Aresponses%E2%80%83to%E2%80%83%20PD-1%E2%80%83inhibition%E2%80%83in%E2%80%83%20metastatic%E2%80%83%20gastric%E2%80%83%0Acancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENat%E2%80%83Med%EF%BC%8C2018%EF%BC%8C24%EF%BC%889%EF%BC%89%EF%BC%9A1449-%0A1458%EF%BC%8E

19、RAJA%E2%80%83U%E2%80%83M%EF%BC%8CGOPAL%E2%80%83G%EF%BC%8CSHIRLEY%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AImmunohistochemical%E2%80%83expression%E2%80%83and%E2%80%83localization%E2%80%83of%E2%80%83%0Acytokines%2Fchemokines%2Fgrowth%E2%80%83factors%E2%80%83in%E2%80%83gastric%E2%80%83cancer%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECytokine%EF%BC%8C2017%EF%BC%8889%EF%BC%89%EF%BC%9A82-90%EF%BC%8E

20、ZHU%E2%80%83X%EF%BC%8CCAO%E2%80%83Y%EF%BC%8CLU%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EEvaluation%E2%80%83of%E2%80%83platelet%E2%80%83%0Aindices%E2%80%83as%E2%80%83diagnostic%E2%80%83biomarkers%E2%80%83for%E2%80%83colorectal%E2%80%83cancer%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Rep%EF%BC%8C2018%EF%BC%8C8%EF%BC%881%EF%BC%89%EF%BC%9A11814%EF%BC%8E

21、WANG%E2%80%83Z%EF%BC%8CLIU%E2%80%83X%EF%BC%8CLIU%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83non-coding%E2%80%83%0ARNA%E2%80%83BLACAT1%E2%80%83promotes%E2%80%83the%E2%80%83tumorigenesis%E2%80%83of%E2%80%83gastric%E2%80%83%0Acancer%E2%80%83by%E2%80%83sponging%E2%80%83microRNA-149-5p%E2%80%83and%E2%80%83targeting%E2%80%83%0AKIF2A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83Manag%E2%80%83Res%EF%BC%8C2020%EF%BC%8812%EF%BC%89%EF%BC%9A%0A6629-6640%EF%BC%8E

22、%E2%80%83%20HU%E2%80%83Y%EF%BC%8CPAN%E2%80%83J%EF%BC%8CWANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83%20noncoding%E2%80%83%0ARNA%E2%80%83linc-UBC1%E2%80%83is%E2%80%83%20negative%E2%80%83%20prognostic%E2%80%83factor%E2%80%83%20and%E2%80%83%0Aexhibits%E2%80%83tumor%E2%80%83pro-oncogenic%E2%80%83activity%E2%80%83in%E2%80%83gastric%E2%80%83cancer%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Clin%E2%80%83Exp%E2%80%83Pathol%EF%BC%8C2015%EF%BC%8C8%EF%BC%881%EF%BC%89%EF%BC%9A594-%0A600%EF%BC%8E

23、CHEN%E2%80%83R%EF%BC%8CZHOU%E2%80%83S%EF%BC%8CCHEN%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%0ABLACAT1%2FmiR-519d-3p%2FCREB1%E2%80%83%20axis%E2%80%83%20mediates%E2%80%83%0Aproliferation%EF%BC%8Capoptosis%EF%BC%8Cmigration%EF%BC%8Cinvasion%EF%BC%8Cand%E2%80%83%0Adrug-resistance%E2%80%83in%E2%80%83colorectal%E2%80%83cancer%E2%80%83progression%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ACancer%E2%80%83Manag%E2%80%83Res%EF%BC%8C2020%EF%BC%8812%EF%BC%89%EF%BC%9A13137-13148%EF%BC%8E

24、LULLI%E2%80%83M%EF%BC%8CNAPOLI%E2%80%83C%EF%BC%8CLANDINI%E2%80%83I%EF%BC%8Cet%E2%80%83al%EF%BC%8ERole%E2%80%83of%E2%80%83%0Anon-coding%E2%80%83RNAs%E2%80%83in%E2%80%83colorectal%E2%80%83cancer%EF%BC%9AFocus%E2%80%83on%E2%80%83long%E2%80%83%0Anon-coding%E2%80%83RNAs%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C2022%EF%BC%8C23%0A%EF%BC%8821%EF%BC%89%EF%BC%9A13431%EF%BC%8E

25、SU%E2%80%83J%EF%BC%8CZHANG%E2%80%83E%EF%BC%8CHAN%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83%20noncoding%E2%80%83%0ARNA%E2%80%83BLACAT1%E2%80%83indicates%E2%80%83a%E2%80%83poor%E2%80%83prognosis%E2%80%83of%E2%80%83colorectal%E2%80%83%0Acancer%E2%80%83and%E2%80%83affects%E2%80%83cell%E2%80%83proliferation%E2%80%83by%E2%80%83epigenetically%E2%80%83%0Asilencing%E2%80%83of%E2%80%83p15%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Death%E2%80%83Dis%EF%BC%8C2017%EF%BC%8C8%0A%EF%BC%883%EF%BC%89%EF%BC%9Ae2665%EF%BC%8E

26、CHUNG%E2%80%83H%E2%80%83C%EF%BC%8CROS%E2%80%83W%EF%BC%8CDELORD%E2%80%83J%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AEfficacy%E2%80%83%20and%E2%80%83%20safety%E2%80%83%20of%E2%80%83%20pembrolizumab%E2%80%83in%E2%80%83%20previously%E2%80%83%0Atreated%E2%80%83advanced%E2%80%83cervical%E2%80%83cancer%EF%BC%9Aresults%E2%80%83from%E2%80%83the%E2%80%83%0Aphase%E2%80%83II%E2%80%83KEYNOTE-158%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83Oncol%EF%BC%8C%0A2019%EF%BC%8C37%EF%BC%8817%EF%BC%89%EF%BC%9A1470-1478%EF%BC%8E

27、ASWATHY%E2%80%83R%EF%BC%8CSUMATHI%E2%80%83S%EF%BC%8ED%20efi%20ni%20n%20g%20%E2%80%83%20n%20e%20w%E2%80%83%0Abiomarkers%E2%80%83for%E2%80%83overcoming%E2%80%83therapeutical%E2%80%83%20resistance%E2%80%83in%E2%80%83%0Acervical%E2%80%83cancer%E2%80%83using%E2%80%83lncRNA%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Biol%E2%80%83Rep%EF%BC%8C%0A2023%EF%BC%8C50%EF%BC%8812%EF%BC%89%EF%BC%9A10445-10460%EF%BC%8E

28、LIU%E2%80%83N%EF%BC%8CHU%E2%80%83G%EF%BC%8CWANG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EL%20n%20c%20R%20N%20A%E2%80%83%0ABLACAT1%E2%80%83%20regulates%E2%80%83VASP%E2%80%83expression%E2%80%83via%E2%80%83%20binding%E2%80%83to%E2%80%83%0AmiR-605-3p%E2%80%83and%E2%80%83promotes%E2%80%83giloma%E2%80%83development%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AJ%E2%80%83Cell%E2%80%83Physiol%EF%BC%8C2019%EF%BC%8C234%EF%BC%8812%EF%BC%89%EF%BC%9A22144-22152%EF%BC%8E

29、CHENG%E2%80%83H%EF%BC%8CTIAN%E2%80%83J%EF%BC%8CWANG%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%0ABLACAT1%E2%80%83is%E2%80%83%20upregulated%E2%80%83in%E2%80%83cervical%E2%80%83%20squamous%E2%80%83cell%E2%80%83%0Acarcinoma%EF%BC%88CSCC%EF%BC%89and%E2%80%83predicts%E2%80%83poor%E2%80%83survival%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AReprod%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C27%EF%BC%882%EF%BC%89%EF%BC%9A585-591%EF%BC%8E

30、WANG%E2%80%83C%E2%80%83H%EF%BC%8CLI%E2%80%83Y%E2%80%83H%EF%BC%8CTIAN%E2%80%83H%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83non-coding%E2%80%83RNA%E2%80%83BLACAT1%E2%80%83promotes%E2%80%83cell%E2%80%83proliferation%EF%BC%8C%0Amigration%E2%80%83%20and%E2%80%83invasion%E2%80%83in%E2%80%83%20cervical%E2%80%83%20cancer%E2%80%83through%E2%80%83%0Aactivation%E2%80%83of%E2%80%83Wnt%2F%CE%B2-catenin%E2%80%83signaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83%0ARev%E2%80%83Med%E2%80%83Pharmacol%E2%80%83Sci%EF%BC%8C2018%EF%BC%8C22%EF%BC%8810%EF%BC%89%EF%BC%9A3002-%0A3009%EF%BC%8E

31、%E2%80%83%20LIU%E2%80%83H%EF%BC%8CZENG%E2%80%83S%E2%80%83Y%EF%BC%8CXIE%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8ELinc-UBC1%E2%80%83%0Astimulates%E2%80%83the%E2%80%83metastasis%E2%80%83and%E2%80%83%20progression%E2%80%83of%E2%80%83ovarian%E2%80%83%0Acancer%E2%80%83via%E2%80%83downregulating%E2%80%83p53%E2%80%83level%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Rev%E2%80%83%0AMed%E2%80%83Pharmacol%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C24%EF%BC%883%EF%BC%89%EF%BC%9A1054-1061%EF%BC%8E

32、%E2%80%83YANG%E2%80%83H%EF%BC%8CQI%E2%80%83Y%EF%BC%8CWANG%E2%80%83X%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EDown%02regulation%E2%80%83%20of%E2%80%83lncRNA%E2%80%83%20BLACAT1%E2%80%83inhibits%E2%80%83%20ovarian%E2%80%83%0Acancer%E2%80%83progression%E2%80%83by%E2%80%83suppressing%E2%80%83the%E2%80%83Wnt%2F%CE%B2-catenin%E2%80%83%0Asignaling%E2%80%83pathway%E2%80%83via%E2%80%83regulating%E2%80%83miR-519d-3p%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMol%E2%80%83Cell%E2%80%83Biochem%EF%BC%8C2020%EF%BC%8C467%EF%BC%881-2%EF%BC%89%EF%BC%9A95-105%EF%BC%8E

33、SUN%E2%80%83W%EF%BC%8CSHEN%E2%80%83NM%EF%BC%8CFU%E2%80%83SL%EF%BC%8EI%20n%20v%20o%20l%20v%20e%20m%20e%20n%20t%E2%80%83%0Aof%E2%80%83%20lncRNA-mediated%E2%80%83%20signaling%E2%80%83%20pathway%E2%80%83%20in%E2%80%83%20the%E2%80%83%0Adevelopment%E2%80%83of%E2%80%83cervical%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Rev%E2%80%83Med%E2%80%83%0APharmacol%E2%80%83Sci%EF%BC%8C2019%EF%BC%8C23%EF%BC%889%EF%BC%89%EF%BC%9A3672-3687%EF%BC%8E

34、%E2%80%83%20LIU%E2%80%83Y%EF%BC%8CHAO%E2%80%83H%EF%BC%8CKANG%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EConstruction%E2%80%83%0Aof%E2%80%83a%E2%80%83%20novel%E2%80%83%20necroptosis-related%E2%80%83lncRNA%E2%80%83%20signature%E2%80%83for%E2%80%83%0Aprognosis%E2%80%83prediction%E2%80%83in%E2%80%83esophageal%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83%0AGastroenterol%EF%BC%8C2022%EF%BC%8C22%EF%BC%881%EF%BC%89%EF%BC%9A345%EF%BC%8E

35、NIU%E2%80%83G%EF%BC%8CZHUANG%E2%80%83H%EF%BC%8CLI%E2%80%83B%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83noncoding%E2%80%83%0ARNA%E2%80%83%20linc-UBC1%E2%80%83%20p%20romotes%E2%80%83%20tumo%20r%E2%80%83%20invasion%E2%80%83%20and%E2%80%83%0Ametastasis%E2%80%83%20by%E2%80%83%20regulating%E2%80%83%20EZH2%E2%80%83%20and%E2%80%83%20repressing%E2%80%83%0AE-cadherin%E2%80%83in%E2%80%83esophageal%E2%80%83squamous%E2%80%83cell%E2%80%83carcinoma%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83BUON%EF%BC%8C2018%EF%BC%8C23%EF%BC%881%EF%BC%89%EF%BC%9A157-162%EF%BC%8E

36、%E2%80%83%20LOU%E2%80%83W%EF%BC%8CDING%E2%80%83B%EF%BC%8CFU%E2%80%83P%EF%BC%8EPseudogene-derived%E2%80%83%0AlncRNAs%E2%80%83%20and%E2%80%83their%E2%80%83miRNA%E2%80%83%20sponging%E2%80%83mechanism%E2%80%83in%E2%80%83%0Ahuman%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83Cell%E2%80%83Dev%E2%80%83Biol%EF%BC%8C2020%0A%EF%BC%888%EF%BC%89%EF%BC%9A85%EF%BC%8E

37、%E2%80%83%20DAI%E2%80%83D%EF%BC%8CFENG%E2%80%83X%E2%80%83D%EF%BC%8CZHU%E2%80%83W%E2%80%83Q%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%0ABLACAT1%E2%80%83regulates%E2%80%83the%E2%80%83viability%EF%BC%8Cmigration%E2%80%83%20and%E2%80%83%0Ainvasion%E2%80%83%20of%E2%80%83%20oral%E2%80%83%20squamous%E2%80%83%20cell%E2%80%83%20carcinoma%E2%80%83%20cells%E2%80%83%20by%E2%80%83%0Atargeting%E2%80%83miR-142-5p%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Rev%E2%80%83Med%E2%80%83Pharmacol%E2%80%83%0ASci%EF%BC%8C2019%EF%BC%8C23%EF%BC%8823%EF%BC%89%EF%BC%9A10313-10323%EF%BC%8E

38、PENG%E2%80%83Y%EF%BC%8CLENG%E2%80%83W%EF%BC%8CDUAN%E2%80%83S%EF%BC%8CHONG%E2%80%83M%EF%BC%8E%0ALong%E2%80%83%20noncoding%E2%80%83RNA%E2%80%83%20BLACAT1%E2%80%83is%E2%80%83%20overexpressed%E2%80%83%0Ain%E2%80%83%20hepatocellular%E2%80%83%20carcinoma%E2%80%83%20and%E2%80%83its%E2%80%83%20downregulation%E2%80%83%0As%20u%20p%20p%20re%20s%20se%20d%E2%80%83%20ca%20nce%20r%E2%80%83%20cell%E2%80%83%20develo%20pme%20nt%E2%80%83%20t%20h%20ro%20ug%20h%E2%80%83%0Aendogenously%E2%80%83competing%E2%80%83against%E2%80%83hsa-miR-485-5p%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Pharmacother%EF%BC%8C2019%EF%BC%88116%EF%BC%89%EF%BC%9A%0A109027%EF%BC%8E

39、YUAN%E2%80%83S%EF%BC%8CTAO%E2%80%83F%EF%BC%8CZHANG%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ERole%E2%80%83%20of%E2%80%83Wnt%2F%CE%B2-Catenin%E2%80%83%20signaling%E2%80%83in%E2%80%83the%E2%80%83%20chemoresistance%E2%80%83%0Amodulation%E2%80%83of%E2%80%83colorectal%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Res%E2%80%83%0AInt%EF%BC%8C2020%EF%BC%882020%EF%BC%89%EF%BC%9A9390878%EF%BC%8E

40、MA%E2%80%83J%E2%80%83H%EF%BC%8CQIN%E2%80%83L%EF%BC%8CLI%E2%80%83X%EF%BC%8ERole%E2%80%83%20of%E2%80%83%20STAT3%E2%80%83%20signaling%E2%80%83%0Apathway%E2%80%83in%E2%80%83breast%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Commun%E2%80%83Signal%EF%BC%8C%0A2020%EF%BC%8C18%EF%BC%881%EF%BC%89%EF%BC%9A33%EF%BC%8E

41、LANTUEJOUL%E2%80%83S%EF%BC%8CSOUND-TSAO%E2%80%83M%EF%BC%8CCOOPER%E2%80%83%0AWA%EF%BC%8Cet%E2%80%83al%EF%BC%8EPD-L1%E2%80%83testing%E2%80%83for%E2%80%83lung%E2%80%83cancer%E2%80%83in%E2%80%832019%EF%BC%9A%0Aperspective%E2%80%83from%E2%80%83the%E2%80%83IASLC%E2%80%83pathology%E2%80%83committee%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0AThorac%E2%80%83Oncol%EF%BC%8C2020%EF%BC%8C15%EF%BC%884%EF%BC%89%EF%BC%9A499-519%EF%BC%8E

42、AALIJAHAN%E2%80%83H%EF%BC%8CGHORBIAN%E2%80%83S%EF%BC%8ELong%E2%80%83%20non-coding%E2%80%83%0ARNAs%E2%80%83and%E2%80%83cervical%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EExp%E2%80%83Mol%E2%80%83Pathol%EF%BC%8C%0A2019%EF%BC%88106%EF%BC%89%EF%BC%9A7-16%EF%BC%8E

43、GOU%E2%80%83C%EF%BC%8CHAN%E2%80%83P%EF%BC%8CLI%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EKnockdown%E2%80%83of%E2%80%83lncRNA%E2%80%83%0ABLACAT1%E2%80%83enhances%E2%80%83%20radiosensitivity%E2%80%83of%E2%80%83head%E2%80%83and%E2%80%83neck%E2%80%83%0Asquamous%E2%80%83cell%E2%80%83carcinoma%E2%80%83cells%E2%80%83by%E2%80%83regulating%E2%80%83PSEN1%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBr%E2%80%83J%E2%80%83Radiol%EF%BC%8C2020%EF%BC%8C93%EF%BC%881108%EF%BC%89%EF%BC%9A20190154%EF%BC%8E

44、WU%E2%80%83X%EF%BC%8CGARDASHOVA%E2%80%83G%EF%BC%8CLAN%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ETargeting%E2%80%83%0Athe%E2%80%83interaction%E2%80%83%20between%E2%80%83RNA-binding%E2%80%83%20protein%E2%80%83HuR%E2%80%83%0Aand%E2%80%83%20FOXQ1%E2%80%83%20suppresses%E2%80%83%20breast%E2%80%83%20cancer%E2%80%83invasion%E2%80%83%20and%E2%80%83%0Ametastasis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECommun%E2%80%83Biol%EF%BC%8C2020%EF%BC%8C3%EF%BC%881%EF%BC%89%EF%BC%9A%0A193%EF%BC%8E

45、%E2%80%83LIU%E2%80%83D%EF%BC%8CERTAY%E2%80%83A%EF%BC%8CHILL%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%20S%20P%20P%201%E2%80%83%0Adeficie%20ncy%E2%80%83%20p%20romote%20s%E2%80%83%20e%20pit%20helial-me%20se%20nc%20hymal%E2%80%83%0Atransition%EF%BC%8Cinvasion%E2%80%83and%E2%80%83metastasis%E2%80%83in%E2%80%83colorectal%E2%80%83cancer%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Death%E2%80%83Dis%EF%BC%8C2020%EF%BC%8C11%EF%BC%884%EF%BC%89%EF%BC%9A224%EF%BC%8E

46、JIANG%E2%80%83M%E2%80%83C%EF%BC%8CNI%E2%80%83J%E2%80%83J%EF%BC%8CCUI%E2%80%83W%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EEmerging%E2%80%83roles%E2%80%83%0Aof%E2%80%83lncRNA%E2%80%83in%E2%80%83cancer%E2%80%83and%E2%80%83therapeutic%E2%80%83opportunities%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAm%E2%80%83J%E2%80%83Cancer%E2%80%83Res%EF%BC%8C2019%EF%BC%8C9%EF%BC%887%EF%BC%89%EF%BC%9A1354-1366%EF%BC%8E

47、YU%E2%80%83Y%EF%BC%8CKOU%E2%80%83D%EF%BC%8CLIU%E2%80%83B%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%20MEG3%E2%80%83%0Acontributes%E2%80%83to%E2%80%83drug%E2%80%83resistance%E2%80%83in%E2%80%83acute%E2%80%83myeloid%E2%80%83leukemia%E2%80%83%0Aby%E2%80%83positively%E2%80%83regulating%E2%80%83ALG9%E2%80%83through%E2%80%83sponging%E2%80%83miR-%0A155%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Lab%E2%80%83Hematol%EF%BC%8C2020%EF%BC%8C42%EF%BC%884%EF%BC%89%EF%BC%9A%0A464-472%EF%BC%8E

48、WANG%E2%80%83M%EF%BC%8CWANG%E2%80%83L%EF%BC%8CHE%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%0ACCAT2%E2%80%83%20promotes%E2%80%83%20radiotherapy%E2%80%83%20resistance%E2%80%83for%E2%80%83%20human%E2%80%83%0Aesophageal%E2%80%83carcinoma%E2%80%83cells%E2%80%83via%E2%80%83the%E2%80%83miR145%2Fp70S6K1%E2%80%83%0Aand%E2%80%83p53%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Oncol%EF%BC%8C2020%EF%BC%8C56%0A%EF%BC%881%EF%BC%89%EF%BC%9A327-336%EF%BC%8E

49、TAN%E2%80%83Y%E2%80%83T%EF%BC%8CLIN%E2%80%83J%E2%80%83F%EF%BC%8CLI%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA-mediated%E2%80%83%0Aposttranslational%E2%80%83modifications%E2%80%83and%E2%80%83%20reprogramming%E2%80%83of%E2%80%83%0Aenergy%E2%80%83metabolism%E2%80%83in%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83Commun%0A%EF%BC%88Lond%EF%BC%89%EF%BC%8C2021%EF%BC%8C41%EF%BC%882%EF%BC%89%EF%BC%9A109-120%EF%BC%8E

1、山东省泰安市科技创新发展项目（2022NS310）()